HBC(SH:603077) Ge Long Hui A P P·2026-01-12 05:58Core Viewpoint - Hebang Biotechnology (603077.SH) experienced a significant drop of 5.15% in stock price, closing at 2.21 yuan, following the announcement of expected losses for the fiscal year 2025 due to asset impairment provisions [1] Financial Performance - The company anticipates a net profit loss for the fiscal year 2025, primarily attributed to the need for asset impairment provisions [1] - The total market capitalization of Hebang Biotechnology is reported at 19.52 billion yuan [1] - The trading volume exceeded 800 million yuan on the day of the announcement [1] Future Actions - Hebang Biotechnology will adhere to relevant regulations and expedite financial accounting and asset impairment testing to promptly disclose the asset impairment provision announcement and the 2025 performance forecast [1] - The data related to the asset impairment provision will be based on figures recognized by the company's auditing agency and confirmed by the board of directors [1] - The official financial data for 2025 will be disclosed in the audited annual report [1]